Molecular structure of (S)-Cetirizine Dihydrochloride, CAS Number: 163837-48-7
(S)-Cetirizine Dihydrochloride (CAS 163837-48-7)
Alternate Names:
(S)-[2-[4-[(4-Chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic Acid Dihydrochloride; (+)-Cetirizine Dihydrochloride; Dextrocetirizine Dihydrochloride
Application:
(S)-Cetirizine Dihydrochloride is a nonsedating type histamine H1-receptor antagonist
CAS Number:
163837-48-7
Molecular Weight:
461.81
Molecular Formula:
C21H25ClN2O3•2HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
(S)-Cetirizine Dihydrochloride is a nonsedating type histamine H1-receptor antagonist. (S)-Cetirizine dihydrochloride is a stable compound under recommended storage conditions, with potential research applications. Its stability makes it suitable for various research studies. It can serve as a reference compound in toxicological studies, providing insights into its absorption, distribution, metabolism, elimination, and safety profile. However, it is important to note that (S)-Cetirizine dihydrochloride is not bioactive or radioactive. Therefore, its research applications may be limited to studies focusing on chemical stability, formulation development, and related areas.
(S)-Cetirizine Dihydrochloride (CAS 163837-48-7) References
- Method development and validation for the simultaneous determination of cetirizine dihydrochloride, paracetamol, and phenylpropanolamine hydrochloride in tablets by capillary zone electrophoresis. | Azhagvuel, S. and Sekar, R. 2007. J Pharm Biomed Anal. 43: 873-8. PMID: 17023136
- Cetirizine dihydrochloride loaded microparticles design using ionotropic cross-linked chitosan nanoparticles by spray-drying method. | Li, FQ., et al. 2010. Arch Pharm Res. 33: 1967-73. PMID: 21191762
- Validated spectroflurimetric determination of some H1 receptor antagonist drugs in pharmaceutical preparations through charge transfer complexation. | el-Din, MK., et al. 2012. J Fluoresc. 22: 175-91. PMID: 21830038
- Formulation and evaluation of novel coated floating tablets of bergenin and cetirizine dihydrochloride for gastric delivery. | He, S., et al. 2012. Drug Dev Ind Pharm. 38: 1280-8. PMID: 22206469
- Determination of stress-induced degradation products of cetirizine dihydrochloride by a stability-indicating RP-HPLC method. | Flórez Borges, P., et al. 2014. Daru. 22: 82. PMID: 25487685
- Risk assessment report of potential impurities in cetirizine dihydrochloride. | Leistner, A., et al. 2020. J Pharm Biomed Anal. 189: 113425. PMID: 32599488
- Flow injection-chemiluminescence determination of cetirizine dihydrochloride in pharmaceuticals using tris(2,2'-bipyridyl)ruthenium (II)-Ag(III) complex reaction. | Moazzam, M., et al. 2021. Luminescence. 36: 674-683. PMID: 33179404
- Spectrophotometric and high performance liquid chromatographic determination of cetirizine dihydrochloride in pharmaceutical tablets. | el Walily, AF., et al. 1998. J Pharm Biomed Anal. 17: 435-42. PMID: 9656155
Inhibitor of:
Histamine H1 Receptor.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(S)-Cetirizine Dihydrochloride, 2.5 mg | sc-208364 | 2.5 mg | $337.00 |